scispace - formally typeset
Open AccessJournal ArticleDOI

Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.

Oscar Chávez-Talavera, +3 more
- 01 May 2017 - 
- Vol. 152, Iss: 7, pp 1679-1694
Reads0
Chats0
TLDR
The most recent findings on the inter-organ signaling and interplay with the gut microbiota of bile acids and their receptors in meta-inflammation are discussed, with a focus on their pathophysiologic roles in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic steatohepatitis, and their potential therapeutic applications.
About: 
This article is published in Gastroenterology.The article was published on 2017-05-01 and is currently open access. It has received 543 citations till now. The article focuses on the topics: G protein-coupled bile acid receptor & Farnesoid X receptor.

read more

Citations
More filters
Journal ArticleDOI

From NASH to HCC: current concepts and future challenges.

Quentin M. Anstee, +6 more
- 01 Jul 2019 - 
TL;DR: This Review discusses NAFLD-associated HCC, including its epidemiology, key features that promote hepatocarcinogenesis and the management of HCC in patients with obesity and associated metabolic comorbidities, and the challenges and future directions of research.
Journal ArticleDOI

Mechanisms and disease consequences of nonalcoholic fatty liver disease

Rohit Loomba, +2 more
- 13 May 2021 - 
TL;DR: In this paper, the authors provide an in-depth discussion of the underlying pathogenetic mechanisms that lead to progressive liver injury, including the metabolic origins of NAS, the effect of NAFLD on hepatic glucose and lipid metabolism, bile acid toxicity, macrophage dysfunction, and hepatic stellate cell activation, and consider the role of genetic, epigenetic and environmental factors that promote fibrosis progression and risk of hepatocellular carcinoma in NASH.
Journal ArticleDOI

Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps.

Amedeo Lonardo, +8 more
- 01 Oct 2019 - 
TL;DR: Clinical trials should be designed to test drug efficacy and safety according to sex, age, reproductive stage (i.e., menopause), and synthetic hormone use, to fill current gaps and implement precision medicine for patients with NAFLD.
Journal ArticleDOI

Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders

Judith Aron-Wisnewsky, +8 more
- 09 Mar 2020 - 
TL;DR: Discrepant microbiome signatures across studies could be linked to the heterogeneity of geographical regions, ethnicity, population characteristics, microbiome sequencing tools, NAFLD diagnostic tools, disease spectrum, drug consumption and circadian rhythm.
Journal ArticleDOI

Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries

Tarini Shankar Ghosh, +30 more
- 01 Jul 2020 - 
TL;DR: The findings support the feasibility of improving the habitual diet to modulate the gut microbiota which in turn has the potential to promote healthier ageing.
References
More filters
Journal ArticleDOI

Bile salt biotransformations by human intestinal bacteria.

Jason M. Ridlon, +2 more
- 01 Feb 2006 - 
TL;DR: The potential exists for altering the bile acid pool by targeting key enzymes in the 7α/β-dehydroxylation pathway through the development of pharmaceuticals or sequestering bile acids biologically in probiotic bacteria, which may result in their effective removal from the host after excretion.
Journal ArticleDOI

Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

Mitsuhiro Watanabe, +12 more
- 26 Jan 2006 - 
TL;DR: It is shown that the administration of BAs to mice increases energy expenditure in brown adipose tissue, preventing obesity and resistance to insulin, and indicates that BAs might be able to function beyond the control of BA homeostasis as general metabolic integrators.
Journal ArticleDOI

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Brent A. Neuschwander-Tetri, +17 more
- 14 Mar 2015 - 
TL;DR: Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification.
Journal ArticleDOI

A Regulatory Cascade of the Nuclear Receptors FXR, SHP-1, and LRH-1 Represses Bile Acid Biosynthesis

Bryan Goodwin, +12 more
- 01 Sep 2000 - 
TL;DR: A potent, nonsteroidal FXR ligand is used to show that FXR induces expression of small heterodimer partner 1 (SHP-1), an atypical member of the nuclear receptor family that lacks a DNA-binding domain that provides a molecular basis for the coordinate suppression of CYP7A1 and other genes involved in bile acid biosynthesis.
Journal ArticleDOI

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis

Takeshi Inagaki, +13 more
- 01 Oct 2005 - 
TL;DR: It is demonstrated that fibroblast growth factor 15 signals from intestine to liver to repress the gene encoding cholesterol 7alpha-hydroxylase (CYP7A1), which catalyzes the first and rate-limiting step in the classical bile acid synthetic pathway.
Related Papers (5)

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Brent A. Neuschwander-Tetri, +17 more
- 14 Mar 2015 - 

Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism.

Annika Wahlström, +4 more
- 12 Jul 2016 - 

Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.

Sama I. Sayin, +10 more
- 05 Feb 2013 - 

Bile salt biotransformations by human intestinal bacteria.

Jason M. Ridlon, +2 more
- 01 Feb 2006 - 

Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

Mitsuhiro Watanabe, +12 more
- 26 Jan 2006 - 
Frequently Asked Questions (2)
Q1. What are the contributions mentioned in the paper "Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia and nafld short title: bile acids in meta-inflammatory disorders" ?

Chávez-Talavera et al. this paper showed that BA concentrations in entero-hepatic tissues regulate metabolism in an inter-organ dialogue between the intestine, its microbiota, and the liver. 

Further studies in this exciting field will determine whether pharmacological modulation of the novel BA metabolism targets ( TGR5, FXR, ASBT, FGF19, CYP8B1 ) will convey beneficial clinical effects in humans.